Daewoong Shares Stem Cell Therapy Expertise to Contribute to Indonesian Patient Care
(Jakarta, February 26th 2025)
Daewoong, a leading global pharmaceutical group from South Korea, announced on February 26th that it has shared its expertise on stem cell applications in treating various diseases with specialist doctors at Eka Hospital BSD, South Tangerang, Banten.
Daewoong invited stem cell expert from South Korea, dr. Kasey Kisu Sung, Vice President of the Korean Stem Cell Therapy Society, specializing in Stem Cell Therapy. Dr. Kasey shared his extensive experience and engaged in direct discussions with medical professionals on the use of stem cells for a range of diseases.
dr. Kasey mentioned "Stem cells and their derivatives play a crucial role in regenerating various organs in patients who have experienced aging. For certain medical conditions, I recommend combining stem cell therapy with standard treatments," and “For example, in cases like osteoarthritis (OA), while standard treatments or surgery remain necessary, adding stem cell therapy can significantly improve patient outcomes. Research worldwide has shown superior results when stem cells are combined with standard treatments for various conditions in orthopedics, neurology, oncology, and aesthetics."
In another session, Daewoong also presented its stem cell product portfolio, sourced from a state-of-the-art stem cell production facility that has received GMP (Good Manufacturing Practice) certification from BPOM.
Daewoong’s advantage lies in its innovative technology and therapeutic manufacturing process, ensuring both safety and quality. By conducting stringent donor screening according to FDA standards (U.S. Food and Drug Administration), Daewoong ensures the safety of its stem cell therapies.
Additionally, its production follows the ISCT (International Society for Cell and Gene Therapy) guidelines, the global standard for cell and gene therapy development. These guidelines provide comprehensive protocols addressing the safety, efficacy, and quality of therapeutic products.
Daewoong also offers a diverse therapy portfolio, including autologous stem cells (derived from the patient’s own body) from adipose tissue and bone marrow, allogeneic stem cells (from donors) from umbilical cords, conditioned media, and immune cells. This technology enables customized treatments based on the specific needs of patients.
Baik In Hyun, Head of Daewoong Biologics Indonesia’s business unit, stated, "We are committed to continuously conducting educational sessions with experienced experts and specialists in the field to ensure that medical professionals in Indonesia can stay updated on the latest stem cell technologies. Stem cell therapy is one of the breakthrough treatments that will see increased usage in the future, contributing to improved healthcare quality for patients in Indonesia."
Daewoong Biologics Indonesia plans to solidify its leadership in the cutting-edge cell therapy market by establishing stable production and supply systems. This transfer is not just about importing technology but also about sparking growth in Indonesia's biopharmaceutical industry. Moreover, there is an ambition to enter global markets, using innovative cell therapies to improve the quality of life for cancer patients worldwide. Driven by ongoing research and development, Daewoong Biologics Indonesia is poised to lead the regenerative medicine sector while advancing its vision to become a global healthcare frontrunner.
Daewoong, a global healthcare group, is helping patients receive better medical care by disseminating medical technology and providing academic support. Since 2021, Daewoong has been sponsoring overseas conferences and fellowship programs to enable young medical professionals to acquire the latest medical knowledge. In particular, since 2022, Daewoong has contributed to strengthening the capabilities of medical professionals by disseminating Korean medical technology to more than 1,000 medical professionals worldwide.
- # # # -
